FY2025 Earnings Estimate for TSE:MDP Issued By Raymond James

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Raymond James lifted their FY2025 earnings per share estimates for Medexus Pharmaceuticals in a research note issued on Monday, February 3rd. Raymond James analyst M. Freeman now forecasts that the company will post earnings of $0.07 per share for the year, up from their prior forecast of $0.03. Raymond James currently has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at ($0.51) EPS, FY2028 earnings at $2.10 EPS and FY2029 earnings at $3.05 EPS.

A number of other research analysts also recently commented on the company. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Ventum Financial boosted their target price on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus raised their price objective on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research note on Thursday, January 30th. Two analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Strong Buy” and a consensus price target of C$6.13.

Medexus Pharmaceuticals Trading Down 19.5 %

TSE MDP opened at C$3.05 on Thursday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The stock has a market cap of C$74.82 million, a P/E ratio of 61.00 and a beta of 1.96. The company’s fifty day simple moving average is C$3.52 and its 200-day simple moving average is C$2.82.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.